SOMERSET, NJ, September 20, 2012 – Cornell Stamoran, Vice President Strategy & Corporate Development at Catalent Pharma Solutions will present “From Enabling Delivery to Delivering Payor, Regulatory & Patient Outcomes: The New Imperative for Advanced Technologies” at the 2nd Annual Partnership Opportunities in Drug Delivery conference on October 2, 2012 in Boston, MA.
This presentation examines increasing expectations medicine developers face in order to obtain improved outcomes - from payors, to regulators, and patients. It discusses the role advanced delivery technology providers play when shifting from ensuring achievement of desired delivery profiles to driving therapeutic benefits. This requires developers and technologists to use different approaches, different partnerships, and different mindsets.
The 2nd Annual Partnership Opportunities in Drug Delivery Conference (PODD) is designed to present a strategic level program for pharmaceutical and biotech business development and external licensing professionals. The event provides a thorough overview of the latest drug delivery technologies available as well as provides a platform for professionals to discuss their development and formulation needs. PODD fosters a meeting place that inspires innovation and advancement of drug development and delivery and offers support for the leaders behind the movement.
Mr. Stamoran has more than 20 years of experience in the pharmaceutical industry. Since joining Catalent in 1992, he has held many roles across a variety of disciplines. During his career, Mr. Stamoran has directly participated in the development of patient adherence and outcomes enhancement strategies for more than 150 innovator drugs. He holds a B.S. degree in accounting and management from the University of Michigan.
For more information on this presentation and to register, please visit:
To schedule an interview with Mr. Stamoran during or after the workshop, please contact Patricia McGee at email@example.com.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
Patricia A. McGee
+1 (732) 537 6407